Zanidatamab shows activity in HER2-amplified metastatic colorectal cancer after multiple prior lines

▸ TREATMENT

A case report demonstrates zanidatamab-based therapy as a potential option for HER2-positive metastatic disease, particularly in patients with cetuximab resistance driven by ERBB2 amplification. (Frontiers in Pharmacology)